Clinical trial
Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial
Name
282009
Description
The study aims to evaluate the reduction in severity and progression of lung injury with three doses of lipid ibuprofen in patients with SARS-CoV-2 infections.
Trial arms
Trial start
2020-05-26
Estimated PCD
2021-05-25
Trial end
2021-09-25
Status
Withdrawn
Phase
Early phase I
Treatment
Ibuprofen
Lipid ibuprofen 200 mg
Arms:
Standard of care plus lipid ibuprofen
Other names:
Flarin
Primary endpoint
Disease progression
14 days
Time to mechanical ventilation
14 days
Eligibility criteria
Inclusion Criteria:
1. Male or female patients aged 18 years and above;
2. Hospitalised;
3. Confirmed or suspected SARS-CoV-2 infection;
4. National Early Warning Score (NEWS2) greater than or equal to 3 in a single parameter or NEWS2 \> 5 overall;
5. Acute hypoxemic respiratory failure: PaO2/FiO2 ratio less than or equal to 300 OR SpO2/FiO2 ratio \< 315 (Kigali Modification)
6. Provision of written informed consent by the patient OR by the patient's Legal Representative OR professional consultee.
Exclusion Criteria:
1. Any of the following contraindications to ibuprofen:
* A known hypersensitivity to ibuprofen or any other constituent of the medicinal product;
* Patients who have previously shown hypersensitivity reactions (e.g. asthma, rhinitis, angioedema or urticaria) in response to aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs);
* Patients with a history of, or existing gastrointestinal ulceration/perforation or bleeding, including that associated with NSAIDs;
* Patients with severe hepatic failure;
* Patients with acute renal failure;
* Patients with severe heart failure.
2. Participation in any other investigational drug products less than 30 days prior to study enrolment;
3. Glasgow Coma Score \< 12;
4. Patients who cannot swallow oral capsules;
5. Pregnant or lactating women;
6. Any medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}
Updated at
2023-07-25
1 organization
1 product
2 indications
Organization
King's College LondonProduct
IbuprofenIndication
COVID-19Indication
Respiratory Distress Syndrome